MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10333574" target="_blank" >RIV/00216208:11110/16:10333574 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/16:10333574 RIV/00023728:_____/16:N0000052

Výsledek na webu

<a href="http://dx.doi.org/10.1186/s13075-016-1023-0" target="_blank" >http://dx.doi.org/10.1186/s13075-016-1023-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13075-016-1023-0" target="_blank" >10.1186/s13075-016-1023-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis

Popis výsledku v původním jazyce

Background: MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates expression of TNF-a, which plays a crucial role in RA pathogenesis. The aim of this study was to determine the treatment outcome of patients with early RA based on the expression of circulating and cellular miR-125b. Methods: Total RNA was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) of 58 patients with early RA before and three months after treatment initiation and of 54 age-and sex-matched healthy controls (HC). The expression of miR-125b was measured by TaqMan quantitative PCR. The treatment responders were defined as patients achieving remission or low disease activity (28-joint count disease activity score (DAS28) <3.2). Receiver operating characteristic (ROC) curve and stepwise backward multivariable logistic regression analyses of miR-125b expression were used to predict the disease outcome at three and six months after initiation of treatment. Results: The expression of miR-125b in the PBMCs and plasma of treatment-naive early RA patients was significantly lower than that of HC and increased significantly after three months of treatment, particularly in responders. However, only the cellular expression of miR-125b was inversely correlated with disease activity. MiR-125b expression in PBMCs was higher in responders than in non-responders after three months (p = 0.042). Using ROC analysis, the cellular expression of miR-125b, but not the disease activity at baseline, predicted the treatment response after three months of therapy (area under the curve 0.652 (95 % CI 0.510 to 0.793); p = 0.048). Conclusion: The expression of miR-125b in PBMCs of treatment-naive patients may present a novel biomarker for monitoring the treatment outcome during the early phase of RA.

Název v anglickém jazyce

MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis

Popis výsledku anglicky

Background: MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates expression of TNF-a, which plays a crucial role in RA pathogenesis. The aim of this study was to determine the treatment outcome of patients with early RA based on the expression of circulating and cellular miR-125b. Methods: Total RNA was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) of 58 patients with early RA before and three months after treatment initiation and of 54 age-and sex-matched healthy controls (HC). The expression of miR-125b was measured by TaqMan quantitative PCR. The treatment responders were defined as patients achieving remission or low disease activity (28-joint count disease activity score (DAS28) <3.2). Receiver operating characteristic (ROC) curve and stepwise backward multivariable logistic regression analyses of miR-125b expression were used to predict the disease outcome at three and six months after initiation of treatment. Results: The expression of miR-125b in the PBMCs and plasma of treatment-naive early RA patients was significantly lower than that of HC and increased significantly after three months of treatment, particularly in responders. However, only the cellular expression of miR-125b was inversely correlated with disease activity. MiR-125b expression in PBMCs was higher in responders than in non-responders after three months (p = 0.042). Using ROC analysis, the cellular expression of miR-125b, but not the disease activity at baseline, predicted the treatment response after three months of therapy (area under the curve 0.652 (95 % CI 0.510 to 0.793); p = 0.048). Conclusion: The expression of miR-125b in PBMCs of treatment-naive patients may present a novel biomarker for monitoring the treatment outcome during the early phase of RA.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14498" target="_blank" >NT14498: Diagnostický a prediktivní význam expresního profilu mikroRNA (miR) u revmatoidní artritidy</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Arthritis Research and Therapy

ISSN

1478-6354

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

June

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000377975700002

EID výsledku v databázi Scopus

2-s2.0-84971569500